Aeterna Zentaris (AEZS) Competitors

Aeterna Zentaris (NASDAQ:AEZS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Do institutionals and insiders believe in AEZS or BCAB?

0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by company insiders. Comparatively, 11.5% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor AEZS or BCAB?

Aeterna Zentaris received 394 more outperform votes than BioAtla when rated by MarketBeat users. However, 65.79% of users gave BioAtla an outperform vote while only 58.28% of users gave Aeterna Zentaris an outperform vote.

Company	Underperform	Outperform
Aeterna Zentaris	Outperform Votes 419 58.28%	Underperform Votes 300 41.72%
BioAtla	Outperform Votes 25 65.79%	Underperform Votes 13 34.21%

Which has more volatility & risk, AEZS or BCAB?

Aeterna Zentaris has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Is AEZS or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat BioAtla's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aeterna Zentaris	-760.32%	-83.45%	-45.76%
BioAtla	N/A	-187.30%	-96.33%

Does the media prefer AEZS or BCAB?

In the previous week, Aeterna Zentaris had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Aeterna Zentaris and 1 mentions for BioAtla. Aeterna Zentaris' average media sentiment score of 0.00 beat BioAtla's score of -0.50 indicating that Aeterna Zentaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aeterna Zentaris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Which has stronger earnings & valuation, AEZS or BCAB?

Aeterna Zentaris has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeterna Zentaris	$2.37M	2.72	-$16.55M	-$14.86	-0.24
BioAtla	$11M	2.03	-$123.46M	-$1.22	-0.31

Do analysts rate AEZS or BCAB?

BioAtla has a consensus price target of $5.00, suggesting a potential upside of 1,208.22%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Aeterna Zentaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aeterna Zentaris	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioAtla	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

BioAtla beats Aeterna Zentaris on 10 of the 18 factors compared between the two stocks.